Literature DB >> 20591089

Surgical cure of hypertension in a patient with MEN 2A syndrome and mixed dopamine, metanephrine pheochromocytoma.

Sergio Chang Figueroa1, Uzma Khan, L Romayne Kurukulasuriya, David Gardner, James R Sowers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20591089      PMCID： PMC8673385          DOI： 10.1111/j.1751-7176.2010.00278.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  17 in total

1.  Germ-line mutations in nonsyndromic pheochromocytoma.

Authors:  Hartmut P H Neumann; Birke Bausch; Sarah R McWhinney; Bernhard U Bender; Oliver Gimm; Gerlind Franke; Joerg Schipper; Joachim Klisch; Carsten Altehoefer; Klaus Zerres; Andrzej Januszewicz; Charis Eng; Wendy M Smith; Robin Munk; Tanja Manz; Sven Glaesker; Thomas W Apel; Markus Treier; Martin Reineke; Martin K Walz; Cuong Hoang-Vu; Michael Brauckhoff; Andreas Klein-Franke; Peter Klose; Heinrich Schmidt; Margarete Maier-Woelfle; Mariola Peçzkowska; Cesary Szmigielski; Charis Eng
Journal:  N Engl J Med       Date:  2002-05-09       Impact factor: 91.245

Review 2.  Multiple endocrine neoplasia type 2. Clinical features and screening.

Authors:  F Raue; K Frank-Raue; A Grauer
Journal:  Endocrinol Metab Clin North Am       Date:  1994-03       Impact factor: 4.741

Review 3.  RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.

Authors:  D J Marsh; L M Mulligan; C Eng
Journal:  Horm Res       Date:  1997

4.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

Review 5.  Pheochromocytoma: presentation, diagnosis and treatment.

Authors:  Nicole Reisch; Mariola Peczkowska; Andrzej Januszewicz; Hartmut P H Neumann
Journal:  J Hypertens       Date:  2006-12       Impact factor: 4.844

6.  Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.

Authors:  Lester D R Thompson
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

7.  Localisation of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2.

Authors:  S E Mole; L M Mulligan; C S Healey; B A Ponder; A Tunnacliffe
Journal:  Hum Mol Genet       Date:  1993-03       Impact factor: 6.150

8.  Risk estimation and screening in families of patients with medullary thyroid carcinoma.

Authors:  B A Ponder; M A Ponder; R Coffey; M E Pembrey; R F Gagel; M Telenius-Berg; P Semple; D F Easton
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

9.  Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s).

Authors:  J A van Heerden; C F Roland; J A Carney; S G Sheps; C S Grant
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

10.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

Authors:  L M Mulligan; C Eng; C S Healey; D Clayton; J B Kwok; E Gardner; M A Ponder; A Frilling; C E Jackson; H Lehnert
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330
View more
  1 in total

Review 1.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.